실적분석 2026년 8월 4일

Henry Schein ($HSIC) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Both Beat, Full-Year Guidance Raised

Earnings Scorecard

Revenue: $3.458 billion (+6.7% YoY, vs. $3.374 billion estimate) ✅ Beat

EPS: Adjusted diluted $1.27 (vs. $1.24 estimate) ✅ Beat

Guidance: Raised — 2026 adjusted diluted EPS $5.29–$5.39, revenue growth 4.5–5.5%, adjusted EBITDA growth mid-to-high single digits

Stock reaction: After-hours +0.22% ($86.7) — as of 08-04 20:32 KST

The Positives

Revenue and earnings both beat: Revenue of $3.458 billion (+6.7%) and adjusted EPS of $1.27 exceeded estimates

Full-year guidance raised: 2026 adjusted EPS, revenue growth, and adjusted EBITDA growth all lifted

Internal growth accelerating: Internal sales +4.6%, with dental consumables and technology segments solid

Henry Schein, which supplies consumables, equipment, and services to dental and medical clinics, posted Q2 total revenue of $3.458 billion, up 6.7% from $3.240 billion a year earlier. The result combines internal growth of 4.6%, acquisitions of 0.7%, and foreign exchange of 1.4%, and came in above the $3.374 billion consensus. Adjusted (non-GAAP) diluted EPS was $1.27, up roughly 15.5% from $1.10 a year earlier, modestly beating the $1.24 analyst estimate. On a GAAP basis, net income attributable to Henry Schein was $94 million, with diluted EPS of $0.82.

By segment, global dental distribution consumables revenue grew 9.7% (internal +5.9%) and global technology revenue grew 8.2% (internal +9.1%), making them clear growth pillars. Adjusted EBITDA was $288 million, up from $256 million a year earlier, and the company said internal local-currency sales growth accelerated from Q1, with the gross margin and early impact of value-creation initiatives pushing earnings higher. On the back of this first-half momentum, the company raised its full-year 2026 outlook.

The Negatives

Equipment growth slowing: Global dental equipment internal growth of 2.2% lagged consumables (5.9%)

Restructuring costs persist: Q2 restructuring-related charges of $29 million pretax recognized

Muted stock reaction: Despite solid results and guidance, after-hours move was limited

The overall picture is healthy, but there are nuances in the details. Consumables and technology/specialty products led growth, while global dental equipment revenue rose just 3.8% (internal 2.2%), suggesting a slower pace of equipment demand recovery. Medical distribution revenue was also steady at 4.0% (internal 3.9%), but did not show the same acceleration as dental consumables.

In addition, Q2 included pretax restructuring-related costs of $29 million, and the full-year guidance is on an adjusted basis excluding restructuring, acquisition-related intangible amortization, value-creation execution costs, and similar items. Since the raised outlook reflects "underlying business trends," reported GAAP earnings may feel lower than the guidance suggests. The fact that the stock did not move much after-hours despite the beat-and-raise combination suggests either that the guidance raise was modest or that expectations were already partly priced in.

What Management Said

CEO Fred Lowery emphasized that broad-based business momentum and execution across the portfolio translated into revenue and margin improvement in Q2, and that the acceleration in internal local-currency sales growth from Q1 was the key driver of earnings growth. He noted the company raised its full-year 2026 outlook based on first-half results and continuing trends, and explained that the value-creation plan (accelerating growth, simplifying the business, operating discipline, and deepening customer relationships) remains the top priority.

The raised guidance takes the adjusted full-year diluted EPS range higher, lifts both ends of the revenue growth target, and steps adjusted EBITDA growth up from "mid-single digits" to "mid-to-high single digits." However, the company did not include any measurement-period gains or tariff-refund benefits in the remaining-year guidance and assumed exchange rates stay at current levels. The tone is confident, but it reads as a stage where the execution payoff from cost savings and portfolio rationalization still needs to be proven with numbers in each upcoming quarter.

Market Reaction and What to Watch Next

The market viewed the adjusted earnings and revenue beats along with the raised full-year guidance as positives, but because the guidance raise was not dramatic and some expectations were already priced in, the after-hours move amounted to only a modest gain. Even when an "earnings beat plus guidance raise" combo prints, the stock often does not jump in one go if the magnitude is limited.

Watch whether internal growth in dental consumables and technology continues to accelerate in Q3.

The pace of equipment revenue recovery and the steadiness of medical distribution growth will shape the overall mix.

It remains to be seen whether margin and adjusted EBITDA improvement from value-creation initiatives track the guidance trajectory relative to the associated costs.